Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Five-Year Retrospective Study in 10 Centers.

Ferdinand R Gerodias, Maria Katrina Tan, Arnold De Guzman,Alisa Bernan, Sue Ann Locnen, Angela Apostol-Alday, Erwin Janino Ybanez,Jose Donato Magno, Alvin Lim, Alex Junia, Ryan Mambulao, Joanne Cosare-San Pedro, Jonald Lucero, Zaldy Quijano, Josephine Apurillo,Arnold John Uson, Jason Louie Lim, Christie Anne Inso, Analigaya Agoncillo-Infante,Roxanne Yen Bongcawil, Gracieux Yuzon Fernando, Amanda Mae Ramos-Manalaysay, Fe-Aileen Arellano-Simon, Elaine Marisse Ilagan-Cargullo, Mariel Joy Bago-Azares, Jamil Baterna,Julie Ann Tapispisan, Noelle Marie Masadao-Rodriguez,Jannah Lee Tarranza, Lorenz Sagayaga Lista,Joar Kent Gumapon

Cardiology research（2022）

引用 1|浏览2

暂无评分

摘要

Among adult breast cancer patients undergoing anthracycline chemotherapy, we determined a high incidence of cardiotoxicity at 9.68%. Having preexisting comorbidities gave patients 12 times increased odds of developing anthracycline cardiotoxicity. The presence of concurrent non-anthracycline chemotherapy showed an inverse association with the development of AIC which we attribute largely to patient selection in a retrospective study. The significantly higher propensity for AIC development in patients with preexisting comorbidities may warrant closer monitoring and control of patient comorbidities such as hypertension among patients undergoing anthracycline chemotherapy.

查看译文

关键词

Anthracycline-induced cardiotoxicity,Anthracyclines,Breast cancer,Cardiomyopathy,Cardiotoxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要